Tenaya Therapeutics (TNYA) Accumulated Depreciation (2020 - 2026)

Tenaya Therapeutics' Accumulated Depreciation history runs 7 years deep, the most recent figure standing at $41.7 million for Q1 2026.

• On a quarterly basis, Accumulated Depreciation rose 19.3% year-over-year to $41.7 million in Q1 2026; TTM through Mar 2026 was $41.7 million, a 19.3% increase from a year earlier, with the FY2025 full-year figure at $39.9 million, up 23.67% from the prior year.
• Accumulated Depreciation climbed to $41.7 million in Q1 2026 per TNYA's latest filing, from $39.9 million in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $41.7 million in Q1 2026 and bottomed at $10.4 million in Q1 2022.
• The 5-year median for Accumulated Depreciation is $26.5 million (2024), against an average of $26.2 million.
• Across the five-year window, Accumulated Depreciation surged 74.09% in 2023 and grew 19.3% in 2026, its largest moves.
• Year by year, Accumulated Depreciation stood at $15.7 million in 2022, then surged by 55.27% to $24.3 million in 2023, then surged by 32.66% to $32.3 million in 2024, then rose by 23.67% to $39.9 million in 2025, then climbed by 4.41% to $41.7 million in 2026.
• Per Business Quant, the three latest TNYA Accumulated Depreciation figures stand at $41.7 million (Q1 2026), $39.9 million (Q4 2025), and $38.9 million (Q3 2025).